Table 3.

Pointwise local defect classification agreement for each subject

Subject number	Test 1–2			Test 1–3			Test 2–3
	CAS	Kappa	Ratioa	CAS	Kappa	Ratioa	CAS	Kappa	Ratioa
Subject 1	83.8	NA	2/9	79.4	0.078	1/13	75.0	0.119	6/11
Subject 2	100.0	NA	0/0	95.6	NA	0/3	95.6	NA	0/3
Subject 3	77.9	NA	0/15	97.1	NA	0/2	80.1	0.193*	13/0
Subject 4	91.2	NA	0/6	92.6	NA	0/5	92.6	0.506**	3/2
Subject 5	88.2	0.376**	1/7	88.2	0.276*	2/6	79.4	0.105	8/6
Subject 6	91.2	0.850**	3/3	91.2	0.852**	2/4	94.1	0.902**	1/3
Subject 7	72.1	0.460**	3/16	60.3	0.304***	3/24	64.7	0.382**	8/16
Subject 8	77.9	0.656**	5/10	86.8	0.789**	6/3	85.3	0.769**	9/1
Subject 9	94.1	0.868**	2/2	80.9	0.608**	4/9	77.9	0.544**	5/10
Subject 10	75.4	0.319***	9/10	81.5	0.463**	7/8	86.2	0.562**	6/6
Subject 11	95.5	0.881**	1/3	82.1	0.613**	5/8	88.1	0.731**	4/5
Subject 12	64.7	0.415**	2/22	75.0	0.595**	2/15	83.8	0.714**	9/2
Subject 13	86.8	0.790**	6/3	95.6	0.926**	1/2	88.2	0.814**	2/6
Subject 14	48.5	NA	7/28	47.1	0.061	4/32	66.2	0.324***	8/15
Subject 15	41.2	NA	20/20	88.2	0.732**	6/2	41.2	NA	22/18
Subject 16	51.5	NA	11/22	51.5	NA	10/23	91.2	0.808**	3/3
Entire cohort	77.1	0.62**	72/176	80.4	0.67**	63/159	80.3	0.68**	107/107

Notes:

^aRatio of number of loci with improvement to number of loci with deterioration in LDC.

^*P<0.05,

^**P<0.001,

^***P<0.005. NA kappa values were unavailable due to cell counts being less than the required minimum.

Abbreviations: CAS, category agreement score; NA, not available; LDC, local defect classification.